Marshall Wace, LLP
- SEC CIK
- 0001318757
- Latest filing
- Aug 13, 2026
NVO holding history
Novo Nordisk A S in every 13F filed by Marshall Wace, LLP, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
NVO overviewAll 13F holders of NVOFull Q2 2026 holdings
- Shares (Q2 2026)
- 1,707,104
- Value
- $81.8M
- % of portfolio
- 0.1%
- Quarters held
- 16
- Since Q3 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 1,707,104 | $81.8M | 0.1% | −1,339,507−44.0% | Reduced | Holders |
| Q1 2026 | 3,046,611 | $112.0M | 0.1% | +2,502,064+459.5% | Added | Holders |
| Q4 2025 | 544,547 | $27.7M | <0.1% | +544,547 | New | Holders |
| Q3 2025 | 0 | $0 | 0.0% | −31,200−100.0% | Sold out | Holders |
| Q2 2025 | 31,200 | $2.15M | <0.1% | +6,075+24.2% | Added | Holders |
| Q1 2025 | 25,125 | $1.74M | <0.1% | −1,142,373−97.8% | Reduced | Holders |
| Q4 2024 | 1,167,498 | $100.4M | 0.1% | +986,195+543.9% | Added | Holders |
| Q3 2024 | 181,303 | $21.6M | <0.1% | −510,138−73.8% | Reduced | Holders |
| Q2 2024 | 691,441 | $98.7M | 0.1% | +689,441+34,472.1% | Added | Holders |
| Q1 2024 | 2,000 | $256.8K | <0.1% | −231,879−99.1% | Reduced | Holders |
| Q4 2023 | 233,879 | $24.2M | <0.1% | +233,879 | New | Holders |
| Q3 2023 | 0 | $0 | 0.0% | −227,832−100.0% | Sold outConverted for a 2-for-1 split | Holders |
| Q2 2023 | 113,916 | $18.4M | <0.1% | +82,160+258.7% | Added | Holders |
| Q1 2023 | 31,756 | $5.05M | <0.1% | +31,756 | New | Holders |
| Q4 2022 | 0 | $0 | 0.0% | −11,592−100.0% | Sold out | Holders |
| Q3 2022 | 11,592 | $1.16M | <0.1% | +11,592 | New | Holders |
| Q2 2022 | 0 | $0 | 0.0% | −3,666−100.0% | Sold out | Holders |
| Q1 2022 | 3,666 | $407.0K | <0.1% | −873−19.2% | Reduced | Holders |
| Q4 2021 | 4,539 | $508.0K | <0.1% | −8,683−65.7% | Reduced | Holders |
| Q3 2021 | 13,222 | $1.27M | <0.1% | +13,222 | New | Holders |